Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007–2010 by Pili Ferrer et al.
Ferrer et al. SpringerPlus  (2015) 4:612 
DOI 10.1186/s40064-015-1398-4
RESEARCH
Sales of macrolides, lincosamides, 
streptogramins, and amoxicillin/clavulanate 
in the in- and outpatient setting in 10 European 
countries, 2007–2010
Pili Ferrer1, Mònica Sabaté1,2,3, Elena Ballarín1,2,3, Joan Fortuny4,5, Marietta Rottenkolber6,7, Sven Schmiedl8,9, 
Joan‑Ramon Laporte1,2,3 and Luisa Ibáñez1,2,3*
Abstract 
Monitoring the use of antibiotics is relevant due to the public health impact of microbial resistance, adverse effects, 
and costs. We present data on the consumption of macrolides, lincosamides, streptogramins and amoxicillin/clavula‑
nate (AMC) between 2007 and 2010 in the in‑and outpatient healthcare setting in 10 European countries provided by 
IMS Health. Antibiotics were classified according to the anatomical therapeutic chemical classification and consump‑
tion was expressed in defined daily doses/1000 inhabitants/day (DIDs). We analysed the number of prescriptions by 
diagnostic codes between 2008 and 2010, based on the International Classification of Diseases, 10th revision (ICD‑10). 
These ICD‑10 codes were grouped into four main categories: respiratory infections, genitourinary infections, other 
infections and other diagnoses. In 2010, the consumption of macrolides and lincosamides ranged from 0.45 DIDs 
(Sweden) to 5.46 DIDs (Italy), and from 0.04 DIDs (Denmark) to 1.00 DID (Germany), respectively. Streptogramins were 
available in France, Germany, Italy, Norway, Spain and United Kingdom with a consumption of <0.001 DID exclusively 
in the hospital setting. The consumption of AMC ranged from <0.001 DIDs (Norway) to 11.67 DIDs (Spain). During the 
study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European 
countries, and lincosamides varied very slightly. Macrolides and AMC were mainly prescribed for respiratory infections 
in all countries but United Kingdom, where most of the prescriptions were assigned to diagnostic codes not clearly 
related with an infection. Lincosamides were prescribed for the respiratory infections and other infections groups. 
There was a wide inter‑country variability in the percentage of the prescriptions assigned to each of the diagnostic 
categories. The inter‑country differences in the consumption of these antibiotics and their prescription by diagnostic 
categories point to an inappropriate use of antibiotics.
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Background
Monitoring the use of antibiotics is relevant due to the 
public health impact of microbial resistance, adverse 
effects, and costs. Several studies have shown wide vari-
ability in the consumption of antibiotics across Europe 
(Coenen et al. 2009; Elseviers et al. 2007). This study was 
designed to compare and analyse the use of macrolides, 
lincosamides, streptogramins, and amoxicillin/clavula-
nate (AMC) in the in- and outpatient setting across 10 
European countries between 2007 and 2010, and to assess 
their indication for use. This study is part of the PRO-
TECT project (“Pharmacoepidemiological Research on 
Outcomes of Therapeutics by a European Consortium”, 
www.imi-protect.eu), which is a collaborative European 
project aimed at developing, testing and disseminating 
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methodological standards for the design, conduct and 
analysis of pharmacoepidemiological studies.
Results
Macrolides, lincosamides, and AMC were more used in 
ambulatory care than they were in the hospital setting 
over the entire study period in all countries. In 2010, the 
proportion of use of macrolides and lincosamides in hos-
pitals out of the total use of macrolides and lincosamides 
ranged from 2.8  % in Norway to 15.0  % in the UK. For 
AMC, this proportion ranged between 5.1 % in Italy and 
41.0  % in the UK. The consumption of streptogramins 
occurred exclusively in the hospital setting.
In 2010, the overall consumption of macrolides ranged 
from 0.45 DIDs in Sweden to 5.46 DIDs in Italy. In France, 
Norway, Poland, Spain, and Sweden, the consumption of 
macrolides continuously decreased over the study period. 
In Denmark, Germany, Italy, and the UK, the consump-
tion of macrolides increased from 1.8 % in Italy to 6.7 % 
in the UK, from 2007 to 2010. In the Netherlands, the use 
of macrolides remained stable (1.46 DIDs). Clarithromy-
cin, azithromycin and erythromycin were the primary 
macrolides consumed in all countries.
The consumption of lincosamides remained stable or 
decreased slightly over the study period in all countries. 
Clindamycin was the primary lincosamine consumed, 
except in Italy, where the most used was lincomycin. 
Because of the low consumption rate of streptogramins 
(<0.0001 DIDs), the results for this group of antibiotics 
will not be discussed further.
From 2007 to 2010, the consumption of AMC increased 
in most countries, especially in Germany (27.6 %) and the 
UK (22.4 %). However, it decreased in Spain by 6.4 % and 
remained stable in Sweden (0.30 DIDs). See Fig. 1 for a 
description of the volume of macrolides, lincosamides, 
streptogramins (MLS) and AMC. See Additional file  1 
for a figure describing erythromycin, clarithromycin, 
azithromycin and other macrolides use between 2007 
and 2010, by country. Additional file  2 supplements the 
information of use of these antibacterial drugs present-
ing figures of their prescription rates by country between 
2008 and 2010.
The consumption of macrolides, lincosamides and 
streptogramins has been presented as a single group of 
antibacterials compared with the consumption of amox-
icillin-clavulanate by country, expressed in defined daily 
doses/1000 inhabitants/day over the study period.
MLS were prescribed for 1045 unique diagnos-
tic codes and AMC was prescribed for 989 differ-
ent diagnostic codes. Prescription rates showed that 
all the antibiotics included in this study were mainly 
prescribed for respiratory infections with slight vari-
ations over the study period that did not change the 
overall pattern. When looking at more detailed diag-
nostic categories related to infections over all the 
study period, macrolides were mainly used for bron-
chitis, pharyngitis, and gastrointestinal infections. 
Lincosamides were mainly prescribed for tonsillitis, 
gastrointestinal infections, and skin infections. Strep-
togramins were mainly prescribed for bronchitis, 
sinusitis and skin infections. AMC was mainly used 
for tonsillitis, bronchitis, otitis media and gastrointes-
tinal infections.
All countries indicated the use of macrolides for 
respiratory infections, with a proportion that var-
ied between 33.2  % in United Kingdom and 85.1  % in 
France. In United Kingdom, macrolides were mainly 
prescribed for the other diagnoses group. France, Neth-
erlands, Spain and the United Kingdom used lincosa-
mides for other diagnoses group, whereas in Germany 
and Poland were mainly used for respiratory infections. 
In Italy, approximately 50 % of the prescriptions of lin-
cosamides were used for other infections. See Figs.  2 
and 3 showing the prescription rates of macrolides and 
lincosamides, respectively, by diagnostic category and 
country. See Additional files 2 and 3 showing a figure of 
the prescription rates of erythromycin, clarithromycin, 
azithromycin and other macrolides by diagnostic cat-
egory and country.
For AMC, the pattern of use was similar to that of 
macrolides over the study period. All countries except 
the United Kingdom used AMC for respiratory infec-
tions, whereas in the United Kingdom 53.5  % of the 
AMC prescriptions were for other diagnoses. The 
percentage of use of AMC for respiratory infections 
ranged between 38.7 % in the Netherlands and 78.9 % in 
France. Bronchitis, tonsilitis and otitis media were the 
main indications for use. Figure  4 shows the prescrip-
tion rates of AMC by diagnostic category and country, 
2008–2010.
Tables 1 and 2 show the percentage distribution of the 
main 10 diagnostic categories for which macrolides and 
AMC were prescribed for, respectively. 
Discussion
This study presented the total consumption of mac-
rolides, lincosamides and AMC from IMS Health. It 
showed a variability of 12.1, 25, and >100-fold for mac-
rolides, lincosamides and AMC, respectively, between 
countries. These antibacterials were mainly consumed in 
the ambulatory setting. This inter-country variability did 
extend to the diagnoses leading to their prescription.
The variability in the consumption of macrolides and 
AMC found in this study could be explained by the differ-
ences that have already been described among the Euro-
pean countries. The South, East and North Europe have 
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been described as high, mild, and low antibacterial con-
sumption countries, respectively (Elseviers et  al. 2007). 
Italy, Poland, and the UK had the highest consumption 
of macrolides. Similarly, France, Italy, and Spain had the 
highest consumption of AMC.
Erythromycin, clarithromycin, and azithromycin were 
the most-used antibiotics in this study across all coun-
tries, between 2007 and 2010. The consumption of mac-
rolides shifted from erythromycin to azithromycin, 
whereas the consumption of clarithromycin remained sta-
ble, and overall, there was a downward trend in the use of 
macrolides. Our results reproduced the results that were 
already described by Cars et al. in 1997 (Cars et al. 2001) 
using the same data provider and confirmed by the Euro-
pean Surveillance of Antimicrobial consumption (ESAC)-
Net report in 2010 (Muller et al. 2010). The trend of the 
increasing consumption of AMC was consistent with the 
results from the ESAC-Net database, except for Spain, 
where the ESAC-Net database showed an increase in 
AMC consumption.
We explored the drug data source for potential expla-
nations for the inter-country variability in drug con-
sumption. The figures corresponding to ambulatory care 
were wholesalers’ sales in all countries, except in the 
Netherlands where they corresponded to the dispensed 
medicines. The figures in hospital consumption were 
wholesalers’ sales in Denmark, Norway, Poland, Sweden, 
and The Netherlands, whereas in the other five countries, 
they corresponded to the dispensed medications.
Problems with population coverage, which includes 
parallel trade, problems with drug data coverage and 
problems with a mix in the registration of antibiotics 
as ambulatory or hospital healthcare setting have been 
described to affect the validity of data when conducting 
cross-national comparison studies (Vander Stichele et al. 
2004).
Fig. 1 Use of macrolides, lincosamides and stretograpmins (MLS) and amoxicillin clavulanate in 10 European countries, 2007–2010
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Beyond the fact that we included ambulatory and hos-
pital healthcare settings, differences in the drug data 
source could explain the higher volume of consumption 
that the IMS data showed in our study compared with 
that of the ESAC-Net database. In the case of antibacte-
rial drugs and countries such as Spain and Italy, whole-
salers’ sales might provide a better estimation of the true 
exposed population to antibiotics, where approximately 
30  % of all antibiotics are sold over-the-counter (Gagli-
otti et al. 2009; Llor et al. 2009). Conversely, the inclusion 
of parallel trade in the wholesalers’ sales could overesti-
mate the antibiotic consumption in Spain, France, and 
Italy, countries that are known to be traditionally parallel 
exporters of pharmaceuticals (Panavos and Costa-Font 
2005).
Other factors impact antibiotic consumption, includ-
ing the number of different brand names (Monnet et al. 
2005), availability of rapid diagnostic tests for upper res-
piratory tract infections (Cals et  al. 2009), cultural dif-
ferences (Deschepper et  al. 2008), and differences in 
healthcare systems (Blommaert et al. 2014).
Spain, Italy, France, and Poland with high consumption 
of antibiotics, were also the countries with highest pre-
scription rates. ICD-10 codes were taken as a proxy for 
indication for use. Although respiratory infections were 
the main diagnostic group assigned to the prescription 
of macrolides and AMC in all countries but United King-
dom, it showed a wide inter-country variability. Coun-
tries with higher consumption of antibiotics were also the 
countries with the higher percentage of these antibiot-
ics prescribed for respiratory infections. A detailed look 
at specific diagnoses categories showed that macrolides 
and AMC are still prescribed for respiratory infections 
for which an antibiotic is not indicated, such as bronchi-
tis or viral upper respiratory tract infections. This pat-
tern of use of antibiotics for respiratory infections have 
been found also in the United States (Roumie et al. 2005; 
Shapiro et  al. 2014), the Netherlands (van den Broek 
d’Obrenan et  al. 2014) and United Kingdom (Petersen 
et al. 2007).
Another of the diagnostic categories often mentioned 
as the main reason for prescribing antibacterial drugs are 
genitourinary infections. In our study, none of the anti-
biotics included are first-choice empirical treatment of 
these infections, except amoxicillin-clavulanate in Spain 
(McQuiston Haslund et  al. 2013). Our results showed 
that Spain was the country with the highest prescription 
rates of AMC for genitourinary infections.
Fig. 2 Prescription rates (×1000) of macrolides by diagnostic category and country, 2008–2010
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The strengths of this study were, first, the inclusion of 
10 European countries. Second, data on ambulatory and 
hospital healthcare settings were available at a population-
based level. Third, the data came from a source different 
from the usual data sources to study antibiotic consump-
tion in Europe, providing a complementary insight to what 
has been published up to now. Fourth, the use of a stand-
ard classification and a common unit of measurement eased 
the cross-national comparison of antibacterials utilisation. 
In addition to the DIDs, information on the consumption 
of antibiotics was provided as prescription rates. Finally, for 
this study information on the indication for use was availa-
ble, raising once again the hypothesis of the potential misuse 
of antibiotics when comparing the results across countries.
One of the limitations of our study was the presenta-
tion of data for 2007–2010, as some prescribing patterns 
may have changed since then. ICD-10 codes, which were 
aggregated at level 3 might have introduced misclassifi-
cation in the different diagnostic groups, as if any of the 
codes at level 4 included an infection as potential cause, 
the diagnostic code was classified in the corresponding 
group of infections. More granular diagnosis data could 
have provided a better insight of the real reason under-
lying each prescription. In addition, there were ICD-10 
codes grouped under the other diagnoses group, which 
included a miscellany of diagnostic codes whose primary 
purpose was not clear. DIDs are used as a proxy of the 
number of people exposed to a medication when it is 
used chronically and only for a single indication, assum-
ing that one DDD corresponds to the prescribed daily 
dose. However, antibiotics are used over short periods 
of time and intermittently; thus, this is a limitation of 
using the DIDs in our study. A more appropriate meas-
ure of the prevalence of exposure to antibiotics would be 
DDDs/1000 inhabitants/year (Capellà 1992). Nonethe-
less, all publications using the ATC/DDD methodology 
expressed antibiotic consumption in DIDs. Finally, not 
knowing the overall prevalence of use of all antibiot-
ics did not allow us to calculate the percentage of use of 
macrolides, lincosamides and streptogramins, and AMC, 
out of the total antibiotic use in each of the countries.
Conclusions
In conclusion, there is a wide variability in the consump-
tion of macrolides and AMC across countries. Along 
with the distribution of the prescription rates by diagno-
ses groups, they reflect differences in the appropriateness 
of use of these antibiotics by country.
Fig. 3 Prescription rates (×1000) of lincosamides by diagnostic categories and country, 2008–2010
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Fig. 4 Prescription rates (×1000) of amoxicillin‑clavulanate by diagnostic category and country, 2008–2010
Table 1 Distribution of  the prescription rates (×1000) of  macrolides by  country and  the 10 most frequently assigned 
diagnostic categories in 2010
Prescription rates (%) France Germany Italy Netherlands Poland Spain United Kingdom
Bronchitis 24.6 (28.0) 34.9 (36.4) 21.3 (17.3) 5.1 (11.4) 30.4 (24.7) 17.8 (10.5) 3.6 (4.3)
Pharyngitis 19.4 (22.1) 6.6 (6.9) 17.3 (14.0) 1.1 (2.4) 15.2 (12.3) 23.2 (13.7) 1.3 (1.5)
Gastrointestinal infections 7.9 (9.0) 1.4 (1.5) 10.4 (8.4) 0.6 (1.3) 1.7 (1.4) 41.9 (24.7) 1.1 (1.3)
Other upper respiratory 
tract infections
4.4 (5.0) 10.9 (11.4) 8.0 (6.5) 3.4 (7.6) 6.6 (5.3) 10.4 (6.1) 4.6 (5.4)
Tonsillitis 0.3 (0.3) 7.3 (7.6) 11.1 (9.0) 2.3 (5.1) 5.5 (4.5) 16.3 (9.6) 1.5 (1.8)
Sinusitis 3.7 (4.2) 8.2 (8.6) 2.6 (2.1) 6.3 (14.0) 9.9 (8.0) 5.1 (3.0) 1.3 (1.5)
Skin infections 1.0 (1.1) 1.6 (1.7) 7.8 (6.3) 6.9 (15.4) 2.7 (2.2) 2.1 (1.2) 10.8 (12.8)
Cold/influenza 6.8 (7.8) 1.1 (1.1) 1.2 (1.0) 0.6 (1.3) 3.2 (2.6) 5.9 (3.5) 0.7 (0.8)
Otitis media 0.8 (0.9) 2.7 (2.8) 3.4 (2.8) 1.9 (4.2) 4.2 (3.4) 6.9 (4.1) 1.5 (1.8)
Pneumonia 1.7 (1.9) 3.0 (3.1) 4.7 (3.8) 1.9 (4.2) 6.4 (5.2) 3.1 (1.8) 0.3 (0.4)
Total prescription rates 
macrolides by country
87.7 95.9 123.2 44.9 123.5 169.3 84.5
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Methods
Antibiotic consumption data were retrieved from 
the Multi-National Integrated Data Analysis System 
(MIDAS, IMS Health). It is a commercial database, which 
collects information on the sales of medicines from 
wholesalers or manufacturers to retail or hospital phar-
macies. Data is sampled and projected to estimate sales 
for all retail and hospital pharmacies in the country. Data 
are registered per drug and all its dosages, and classified 
according to the Anatomical Classification of Pharma-
ceutical Products of the European Pharmaceutical Mar-
keting Research Association (EphMRA). A booklet with 
the equivalences between the EphMRA classification 
and the Anatomical Therapeutic Chemical Classification 
(ATC) of the World Health Organization (WHO) (Euro-
pean Pharmaceutical Market Research 2013) allowed the 
classification of antibiotics for this study according to 
the 2013 version of the WHO ATC classification (WHO 
Collaborating Centre for Drug Statistics and Methodol-
ogy 2015). The volume of consumption was expressed 
in defined daily doses (DDDs) per 1000 inhabitants and 
per day (DIDs). Population denominators were extracted 
from the official national statistics websites, reflecting the 
population at the end of the year.
Hospital and ambulatory consumption of macrolides 
(J01FA), lincosamides (J01FF), streptogramins (J01FG), 
and AMC (J01CR02) were analysed. The use of these 
antibacterials was assessed in Denmark, France, Ger-
many, Italy, Norway, Poland, Spain, Sweden, the Nether-
lands and the United Kingdom between 2007 and 2010.
The selection of these antibiotics are part of the PRO-
TECT project goals and conform to criteria described 
elsewhere (Abbing-Karahagopian et  al. 2014). In sum-
mary, five key drug-adverse event pairs were selected 
fulfilling a set of a priori defined criteria that considered 
the public health impact of the adverse event and the pos-
sibility of studying a wide range of methodological aspects 
in pharmacoepidemiology. We categorised macrolides in 
erythromycin, clarithromycin, azithromycin, and other 
macrolides. The other macrolides group showed the wid-
est variation in data availability between countries accord-
ing to the different marketing authorisations across the 
countries. Clindamycin and lincomycin were approved 
in France, Germany, Italy, Poland, and Spain. Clinda-
mycin was only approved in Denmark, the Netherlands, 
Norway, Sweden and the UK. For the streptogramins 
group, only quinupristin/dalfopristin was approved in 
France, Germany, Italy, Netherlands, Norway, Spain and 
the UK at the time of the study. For Denmark and Swe-
den only the combined in- and outpatient consumption 
data were provided. Between 2008 and 2010, data on the 
number of prescriptions sorted by diagnosis according to 
the International Classification of Diseases, 10th revision 
(ICD-10) (International Classification of Diseases, 10th 
revision 2015) were available for seven countries. IMS 
Health provided all physicians’ diagnosis and the treat-
ment prescribed aggregated at country level. The diag-
nostic codes were given at three character-categories. 
We classified them into 45 categories, which were further 
assembled into four main groups: “respiratory infections”, 
“genitourinary infections”, “other infections”, and “other 
diagnoses”. Respiratory infections included the diagnostic 
codes for cold/influenza, pharyngitis, tonsillitis, laryngi-
tis, sinusitis, otitis media, other diseases of the ear, bron-
chitis, pneumonia, unspecified respiratory disorders and 
other upper and lower respiratory tract infections. Geni-
tourinary infections included upper- and lower urinary 
infections, male and female genital infections and other 
Table 2 Distribution of  the prescription rates (×1000) of  AMC by  diagnostic by  country and  the 10 most frequently 
assigned diagnostic categories in 2010
Prescription rates (%) France Germany Italy Netherlands Poland Spain United Kingdom
Bronchitis 15.2 (20.2) 1.8 (15.3) 14.1 (10.1) 3.2 (6.6) 15.0 (13.7) 17.0 (7.1) 1.2 (2.7)
Pharyngitis 8.9 (11.9) 0.2 (1.7) 17.4 (12.4) 0.3 (0.6) 15.7 (14.4) 8.0 (3.3) 0.2 (0.4)
Gastrointestinal infections 2.7 (3.6) 0.3 (2.5) 20.1 (14.4) 1.7 (3.5) 1.3 (1.2) 43.3 (18.0) 1.3 (2.9)
Other upper respiratory 
tract infections
2.4 (3.2) 0.4 (3.4) 8.8 (6.3) 1.4 (2.9) 6.0 (5.5) 12.8 (5.3) 1.2 (2.7)
Tonsillitis 0.6 (0.8) 1.1 (9.3) 20.6 (14.7) 1.6 (3.3) 18.2 (16.7) 35.8 (14.9) 0.3 (0.7)
Sinusitis 8.4 (11.2) 0.9 (7.6) 3.0 (2.1) 3.2 (6.6) 7.9 (7.2) 6.0 (2.5) 0.7 (1.6)
Skin infections 2.6 (3.5) 1.8 (15.3) 8.1 (5.8) 8.1 (16.8) 3.5 (3.2) 15.4 (6.4) 4.1 (9.1)
Cold/influenza 3.1 (4.1) 0.03 (0.3) 1.2 (0.9) 0 (0) 2.6 (2.4) 2.8 (1.2) 0.3 (0.7)
Otitis media 13.9 (18.5) 0.7 (5.9) 11.1 (7.9) 2.6 (5.4) 10.9 (10.0) 24.6 (10.2) 0.8 (1.8)
Pneumonia 2.5 (3.3) 0.8 (6.8) 1.5 (1.1) 4.7 (9.7) 2.7 (2.5) 5.7 (2.4) 0.2 (0.4)
Total prescription rates AMC 
by country
75.1 11.8 139.9 48.3 109.3 240.2 45.1
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unspecified genito-urinary infections. The group other 
infections included different infections by anatomic organ 
as specified in the ICD classification and other bacterial, 
viral, protozoal and helminthic infections. The other diag-
nosis group refers to any diagnostic code not suggestive 
of an infection disease and it includes the rest of diseases 
included in the ICD classification. The prescription rate 
(×1000 inhabitants and year), by country, drug, and diag-
nosis group was estimated. As in the calculation of DIDs, 
population denominators were retrieved from the official 
national statistics websites.
The sources of drug consumption data were explored 
as sources of variation in drug consumption across the 
countries. See Table 3.
All analyses were conducted using Microsoft Excel 
2007® (Microsoft Corporation, Redmond, WA, USA) and 
STATA13.1® (StataCorpLP, College Station, TX, USA).
Ethical approval Not required.
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